Osemitamab by Transcenta for Metastatic Biliary Tract Cancer: Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Osemitamab overview

Osemitamab (TST-001) is under development for the treatment of solid tumor including gastric cancer, gastroesophageal junction cancer, colorectal cancer, metastatic adenocarcinoma of the pancreas, adenocarcinoma of the gastroesophageal junction, metastatic biliary tract cancer, pancreatic ductal adenocarcinoma, cholangiocarcinoma, ovarian cancer, colon cancer, gallbladder cancer and lung cancer. The drug candidate is an humanized monoclonal antibody which acts by targeting claudin18.2. It is administered through intravenous route. It is based on Transcenta’s Immune Tolerance Breaking Technology (IMTB) platform.

Transcenta overview

Transcenta (Transcenta Holding) that is a global biotherapeutics company that fully integrates antibody-based biotherapeutics discovery, development and manufacturing. The company is headquartered in Suzhou, Shanghai, China.

For a complete picture of Osemitamab’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.